Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga , Turin, Italy.
Department of Oncology, University of Turin, Azienda Ospedaliera Ordine Mauriziano , Turin, Italy.
Expert Rev Anticancer Ther. 2021 Jan;21(1):23-32. doi: 10.1080/14737140.2021.1837629. Epub 2020 Oct 22.
Luteinized thecoma (thecomatosis) with sclerosing peritonitis (LTSP) is a very uncommon syndrome, characterized by the presence of single or bilateral ovarian thecomas and peritoneal fibrotic lesions. The disease occurs in young women and it can lead to peritoneal fibrosis and bowel obstruction. The pathogenesis of this syndrome remains still largely unknown. Surgery represents the cornerstone of treatment, but resection alone does not always allow a complete disease control. Attempts at medical treatments have been reported in recent years, but a real standard therapy has not yet been defined.
We performed a systematic review of literature, collecting all the papers that reported cases of LTSP, since its first description in 1994. We found that, in these 25 years, less than 50 cases have been described in literature.
Along with the established role of surgery, adjuvant treatment with hormonal agents, in particular in estrogen receptor expression, seems to be a promising approach. However, more efforts must be carried out to describe treatment and outcome of new cases, improving knowledge about this rare condition.
黄体化间质细胞瘤伴硬化性腹膜炎(LTSP)是一种非常罕见的综合征,其特征是存在单个或双侧卵巢间质细胞瘤和腹膜纤维性病变。这种疾病发生在年轻女性中,可导致腹膜纤维化和肠梗阻。该综合征的发病机制仍很大程度上未知。手术是治疗的基石,但单独切除并不总是能完全控制疾病。近年来已经有报道尝试使用药物治疗,但尚未确定真正的标准治疗方法。
我们进行了文献系统回顾,收集了自 1994 年首次描述以来所有报告 LTSP 病例的论文。我们发现,在这 25 年中,文献中描述的病例不到 50 例。
除了手术的既定作用外,激素药物的辅助治疗,特别是在雌激素受体表达方面,似乎是一种很有前途的方法。然而,为了更好地描述这种罕见疾病的治疗和预后,还需要做出更多的努力来描述新病例的治疗和结果。